Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate

Vaccine

Volumn 18, Issue 3-4, 1999, Pages 259-267

  Klinguer, Christine ^b   David, Dominique ^b   Kouach, Mostafa ^a   Wieruszeski, Jean Michel ^b   Tartar, André ^a,b   Marzin, Daniel ^a,c   Levy, Jean Paul ^d   Gras Masse, Hélène ^a,b  

^a UNIV LILLE   (France)

^b INSTITUT DE BIOLOGIE DE LILLE   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d INSTITUT COCHIN   (France)

Author keywords

Characterization; Lipopeptide; Synthetic vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; CONFERENCE PAPER; DRUG MANUFACTURE; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV-1; LIPOPROTEINS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDES; RABBITS;

EID: 0032862292     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00196-6     Document Type: Conference Paper

References (33)

1. Gras-Masse H, Martinon F, Sergheraert C, Levy J-P, Magne R, Tartar A, Boutillon C, Gomard E. Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines. Patent No. EP0491628 (1992-06-24); US5871746 (1999-02-16).
2. Martinon F., Gras-Masse H., Boutillon C., Chirat F., Deprez B., Guillet J.G., Gomard E., Tartar A., Levy J.P. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. J Immunol. 149:1992;3416-3422.
3. Sauzet J.P., Deprez B., Martinon F., Guillet J.G., Gras-Masse H., Gomard E. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric multi-restricted lipopeptides. Vaccine. 13:(14):1995;1339-1345.
4. Ferru I., Rollin C., Estaquier J., Sutton P., Delacre M., Tartar A., Gras-Masse H., Auriault C. Comparison of the immune response elicited by a free peptide and a lipopeptide construct. Peptide Res. 9:1996;136-143.
5. Deprez B., Sauzet J.P., Boutillon C., Martinon F., Tartar A., Sergheraert C., Guillet J.G., Gomard E., Gras-Masse H. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine. 14:1996;375-382.
6. BenMohamed L., Gras-Masse H., Tartar A., Daubersies P., Brahimi K., Thomas A., Druilhe P. Lipopeptide immunisation without adjuvant induces potent and long-lasting B, Th and CTL responses against a malaria liver stage antigen in mice and chimpanzee(s). Eur J Immunol. 27:1997;1242-1253.
7. Bourgault I., Chirat F., Tartar A., Lévy J.-P., Guillet J.-G., Venet A. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides. J Immunol. 152:(5):1994;2530-2537.
8. Villada I., Mortara L., Aubertin A.-M., Gras-Masse H., Lévy J.-P., Guillet J.-G. Positive role of macaque cytotoxic T lymphocytes during SIV infection: decrease of cellular viremia and increase of asymptomatic clinical period. FEMS Immunol Med Microbiol. 19:(1):1997;81-87.
9. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., Yuan L., Chisari F.V., Furze J., Bartholomeuz R., et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest. 95:(1):1995;341-349.
10. Livingston B.D., Crimi C., Grey H., Ishioka G., Chisari F.V., Fikes J., Grey H., Chesnut R.W., Sette A. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol. 159:(3):1997;1383-1392.
11. Rowland-Jones S., Tan R., McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol. 65:1997;277-346.
12. Jassoy C., Walker B.D. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Semin Immunopathol. 18:(3):1997;341-354.
13. Oldstone M.B. HIV versus cytotoxic T lymphocytes: the war being lost. N Engl J Med. 337:(18):1997;1306-1308.
14. Diamond D.J., York J., Sun J.Y., Wright C.L., Forman S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 90:(5):1997;1751-1767.
15. Stuhler G., Schlossman S.F. Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets. Proc Natl Acad Sci USA. 21:(2):1997;622-627.
16. Sauzet J.P., Gras-Masse H., Guillet J.-G., Gomard E. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. Int Immunol. 4:1996;457-465.
17. Mortara L., Letourneur F., Gras-Masse H., Venet A., Guillet J.G., Villada I.B. Selection of virus varaints and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol. 72:(2):1998;1403-1409.
18. Gahery H et al. In preparation.
19. Atherton E., Sheppard R.C. Solid phase synthesis. A practical approach. 1989;IRL Press.
20. Fields G.B., Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxy carbonyl amino acids. Int J Pept Prot Res. 35:1990;161-214.
21. Knorr R., Trzeciak A., Bannwarth W., Gillesen D. New coupling reagents in peptide chemistry. Jung G., Bayer E. Proceedings of the 20th European Peptide Symposium, Tuebingen. 1989;37-39 W. de Gruyter, Berlin.
22. Griesinger C., Otting G., Wüthrich K., Ernst R.R. Clean-TOCSY for 1H spin system identification in macromolecules. J Am Chem Soc. 110:1988;7870-7872.
23. Wider G., Macura S., Kumar A., Ernst R.R., Wüthrich K. Homonuclear two-dimensional 1H NMR of proteins: experimental procedures. J Magn Reson. 56:1984;207-234.
24. Smart S.S., Mason T.J., Bennell P.S., Maeij N.J., Geysen H.M. High-throughput purity estimation and characterisation of synthetic peptides by electrospray mass spectrometry. Int J Pept Protein Res. 47:(1-2):1996;47-55.
25. Hsieh K.H., Demaine M.M., Gurusidaiah S. Side reactions in solid-phase peptide synthesis and their applications. Int J Pept Protein Res. 483:1996;292-298.
26. Dölling R, Beyermann M, Haenel J, Kernchen F, Krause E, Franke P, Brudel M, Bienert M. Piperidine-mediated side product formation for Asp(OBut)-containing peptides. J Chem Soc Chem Commun 1994; 853-4.
27. Gitlin G., Tsarbopoulos A., Patel S.T., Sydor W., Pramanik B.N., Jacobs S., Westreich L., Mittelman S., Bausch J.N. Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b. Pharm Res. 5:1996;762-769.
28. Barany G, Merrifield RB. Solid-phase peptide synthesis. In: Gross E, Meienhoffer J, editors. The peptides, analysis, synthesis, biology. Academic Press, 1980. vol. 2, p. 2-284.
29. Simat T.J., Steinhart H. Oxidation of free tryptophan and tryptophan residues in peptides and proteins. J Agricult Food Chem. 46:(2):1998;490-498.
30. Riniker B., Hartmann A. Deprotection of peptides containing Arg(Pmc) and tryptophan or tyrosine: elucidation of by-products. Rivier J.E., Marshall G.R. Proceedings of the 11th American Peptide Symposium. 1980;950-952 ESCOM, Leiden.
31. Gras-Masse H, Lippens G, Wieruszeski J-M, Tartar A, Bossus M, Bourgault-Villada, I, Guillet J-G. Micelles mixtes de lipopeptides pour l'induction d'une réponse immunitaire et leurs utilisations à des fins thérapeutiques. Patent No. FR 97 15246, 1997-03-12.
32. Aswad D.W. Deamidation and isoaspartate formation in peptides and proteins. 1995;CRC Press, Boca Raton.
33. Chen W., Ede N.J., Jackson D.C., McCluskey J., Purcell A.W. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J Immunol. 157:1996;1000-1005.